All In MedTech

Device Trial Radar · NCT07563231

Polymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes

POLARIS : POLymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Jun 2028

Study completion Jun 2036

Sponsor

Lead sponsor
Dorian GarinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

POLARIS is a prospective, single-centre, single-arm observational pilot registry evaluating the real-world safety and efficacy of the Focus np (Abluminus np, Concept Medical, Tampa, FL, USA) polymer-free sirolimus-eluting stent in consecutive adult patients undergoing percutaneous coronary intervention (PCI). The primary endpoint is target lesion failure (TLF) at 12 months, defined per Academic Research Consortium-2 (ARC-2) criteria as the device-oriented composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation. Patients treated since January 2021 will be retrospectively identified and prospectively consented, with follow-up through 5 years. The registry will provide the first Western clinical evidence on this CE-marked device and serve as a template for a future national Swiss multicentre registry.

Conditions

  • Coronary Artery Disease
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Stent Thrombosis
  • Percutaneous Coronary Intervention

Interventions

  • Polymer-free sirolimus-based submicron carrier-eluting stent Focus np (Abluminus np, Concept Medical, Tampa, FL, USA)Device

    Thin-strut (73 micrometres) cobalt-chromium coronary stent with polymer-free submicron phospholipid carriers (200-300 nm) delivering sirolimus exclusively to the abluminal surface, and fusion coating extending sirolimus deposition up to 5 mm beyond the stent edges. CE-marked 24 January 2020. Available diameters 2.25-4.0 mm and lengths 8-40 mm. Manufactured by Concept Medical, Tampa, FL, USA. Implantation and peri-procedural care follow operator discretion and institutional standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target Lesion Failure (TLF)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Geneva University Hospitals (HUG) - Service of Cardiology

    Geneva, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.